To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Martha L. Van Dam, M.S., LMHC, NCC
Katie Kosko
A 16-member team, including five patients with multiple myeloma, hiked through Iceland to raise money for disease research in hopes of finding a cure.
Kristie L. Kahl
Nicholas J. Vogelzang, M.D., FASCO, FACP, has seen cancer through a variety of lenses – from oncologist to patient as well as caregiver – giving him a different perspective than most.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Kristie L. Kahl
A study published in Blood demonstrated the significant disparities found between insurance status and survival outcomes in patients of all ages with follicular lymphoma.
Stephen Labay
Twenty-year-old men think they are invincible. They wake up each morning thinking that nothing can stop them and that is one of the best feelings in the world.
Kristie L. Kahl
The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable